219 related articles for article (PubMed ID: 35328014)
1. Aspirin Colorectal Cancer Prevention in Lynch Syndrome: Recommendations in the Era of Precision Medicine.
Serrano D; Patrignani P; Stigliano V; Turchetti D; Sciallero S; Roviello F; D'Arpino A; Grattagliano I; Testa S; Oliani C; Bertario L; Bonanni B
Genes (Basel); 2022 Mar; 13(3):. PubMed ID: 35328014
[TBL] [Abstract][Full Text] [Related]
2. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial.
Burn J; Sheth H; Elliott F; Reed L; Macrae F; Mecklin JP; Möslein G; McRonald FE; Bertario L; Evans DG; Gerdes AM; Ho JWC; Lindblom A; Morrison PJ; Rashbass J; Ramesar R; Seppälä T; Thomas HJW; Pylvänäinen K; Borthwick GM; Mathers JC; Bishop DT;
Lancet; 2020 Jun; 395(10240):1855-1863. PubMed ID: 32534647
[TBL] [Abstract][Full Text] [Related]
3. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.
Burn J; Gerdes AM; Macrae F; Mecklin JP; Moeslein G; Olschwang S; Eccles D; Evans DG; Maher ER; Bertario L; Bisgaard ML; Dunlop MG; Ho JW; Hodgson SV; Lindblom A; Lubinski J; Morrison PJ; Murday V; Ramesar R; Side L; Scott RJ; Thomas HJ; Vasen HF; Barker G; Crawford G; Elliott F; Movahedi M; Pylvanainen K; Wijnen JT; Fodde R; Lynch HT; Mathers JC; Bishop DT;
Lancet; 2011 Dec; 378(9809):2081-7. PubMed ID: 22036019
[TBL] [Abstract][Full Text] [Related]
4. Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC).
Burn J; Mathers J; Bishop DT
Recent Results Cancer Res; 2013; 191():157-83. PubMed ID: 22893205
[TBL] [Abstract][Full Text] [Related]
5. Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study.
Movahedi M; Bishop DT; Macrae F; Mecklin JP; Moeslein G; Olschwang S; Eccles D; Evans DG; Maher ER; Bertario L; Bisgaard ML; Dunlop MG; Ho JW; Hodgson SV; Lindblom A; Lubinski J; Morrison PJ; Murday V; Ramesar RS; Side L; Scott RJ; Thomas HJ; Vasen HF; Burn J; Mathers JC
J Clin Oncol; 2015 Nov; 33(31):3591-7. PubMed ID: 26282643
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention in Lynch syndrome.
Burn J; Mathers JC; Bishop DT
Fam Cancer; 2013 Dec; 12(4):707-18. PubMed ID: 23880960
[TBL] [Abstract][Full Text] [Related]
7. General practitioner attitudes towards prescribing aspirin to carriers of Lynch Syndrome: findings from a national survey.
Smith SG; Foy R; McGowan J; Kobayashi LC; Burn J; Brown K; Side L; Cuzick J
Fam Cancer; 2017 Oct; 16(4):509-516. PubMed ID: 28434157
[TBL] [Abstract][Full Text] [Related]
8. Aspirin and colorectal cancer prevention in Lynch syndrome.
Chan AT; Lippman SM
Lancet; 2011 Dec; 378(9809):2051-2. PubMed ID: 22036018
[No Abstract] [Full Text] [Related]
9. Lynch syndrome: history, causes, diagnosis, treatment and prevention (CAPP2 trial).
Burn J; Mathers J; Bishop DT
Dig Dis; 2012; 30 Suppl 2():39-47. PubMed ID: 23207931
[TBL] [Abstract][Full Text] [Related]
10. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
[TBL] [Abstract][Full Text] [Related]
11. Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial.
Soualy A; Deutsch D; Benallaoua M; Ait-Omar A; Mary F; Helfen S; Boubaya M; Levy V; Benamouzig R;
Trials; 2020 Sep; 21(1):764. PubMed ID: 32887653
[TBL] [Abstract][Full Text] [Related]
12. Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.
Mathers JC; Movahedi M; Macrae F; Mecklin JP; Moeslein G; Olschwang S; Eccles D; Evans G; Maher ER; Bertario L; Bisgaard ML; Dunlop M; Ho JW; Hodgson S; Lindblom A; Lubinski J; Morrison PJ; Murday V; Ramesar R; Side L; Scott RJ; Thomas HJ; Vasen H; Gerdes AM; Barker G; Crawford G; Elliott F; Pylvanainen K; Wijnen J; Fodde R; Lynch H; Bishop DT; Burn J;
Lancet Oncol; 2012 Dec; 13(12):1242-9. PubMed ID: 23140761
[TBL] [Abstract][Full Text] [Related]
13. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome.
Burn J; Bishop DT; Mecklin JP; Macrae F; Möslein G; Olschwang S; Bisgaard ML; Ramesar R; Eccles D; Maher ER; Bertario L; Jarvinen HJ; Lindblom A; Evans DG; Lubinski J; Morrison PJ; Ho JW; Vasen HF; Side L; Thomas HJ; Scott RJ; Dunlop M; Barker G; Elliott F; Jass JR; Fodde R; Lynch HT; Mathers JC;
N Engl J Med; 2008 Dec; 359(24):2567-78. PubMed ID: 19073976
[TBL] [Abstract][Full Text] [Related]
14. Daily aspirin reduces colorectal cancer incidence in patients with Lynch syndrome.
Barton MK
CA Cancer J Clin; 2012; 62(3):143-4. PubMed ID: 22411104
[No Abstract] [Full Text] [Related]
15. Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome.
Ait Ouakrim D; Dashti SG; Chau R; Buchanan DD; Clendenning M; Rosty C; Winship IM; Young JP; Giles GG; Leggett B; Macrae FA; Ahnen DJ; Casey G; Gallinger S; Haile RW; Le Marchand L; Thibodeau SN; Lindor NM; Newcomb PA; Potter JD; Baron JA; Hopper JL; Jenkins MA; Win AK
J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26109217
[TBL] [Abstract][Full Text] [Related]
16. Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts.
Buchanan DD; Clendenning M; Rosty C; Eriksen SV; Walsh MD; Walters RJ; Thibodeau SN; Stewart J; Preston S; Win AK; Flander L; Ouakrim DA; Macrae FA; Boussioutas A; Winship IM; Giles GG; Hopper JL; Southey MC; English D; Jenkins MA
J Gastroenterol Hepatol; 2017 Feb; 32(2):427-438. PubMed ID: 27273229
[TBL] [Abstract][Full Text] [Related]
17. GPs' willingness to prescribe aspirin for cancer preventive therapy in Lynch syndrome: a factorial randomised trial investigating factors influencing decisions.
Lloyd KE; Hall LH; Ziegler L; Foy R; Borthwick GM; MacKenzie M; Taylor DG; Smith SG;
Br J Gen Pract; 2023 Apr; 73(729):e302-e309. PubMed ID: 36997217
[TBL] [Abstract][Full Text] [Related]
18. Aspirin and low-dose nitric oxide-donating aspirin increase life span in a Lynch syndrome mouse model.
McIlhatton MA; Tyler J; Kerepesi LA; Bocker-Edmonston T; Kucherlapati MH; Edelmann W; Kucherlapati R; Kopelovich L; Fishel R
Cancer Prev Res (Phila); 2011 May; 4(5):684-93. PubMed ID: 21436383
[TBL] [Abstract][Full Text] [Related]
19. Exploring clinicians' attitudes about using aspirin for risk reduction in people with Lynch Syndrome with no personal diagnosis of colorectal cancer.
Chen Y; Peate M; Kaur R; Meiser B; Wong T; Kirk J; Ward RL; Goodwin A; Macrae F; Hiller J; Trainer AH; Mitchell G
Fam Cancer; 2017 Jan; 16(1):99-109. PubMed ID: 27677266
[TBL] [Abstract][Full Text] [Related]
20. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives.
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2009 Jan; 11(1):35-41. PubMed ID: 19125126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
